Description

Sio Gene Therapies Inc. is a biotechnology company in the clinical development phase, committed to pioneering gene therapies designed to fundamentally alter the prognosis for patients afflicted with neurodegenerative conditions. Its therapeutic pipeline is supported by strategic licensing agreements, including one with Oxford BioMedica (UK) Ltd. for the advancement and market introduction of AXO-Lenti-PD and associated gene therapy offerings. Furthermore, Sio Gene Therapies collaborates with The University of Massachusetts Medical School on the development and commercialization of other gene therapy candidates, notably AXO-AAV-GM1 and AXO-AAV-GM. Incorporated in 2014 and headquartered in New York, New York, the entity was known as Axovant Gene Therapies Ltd. prior to its renaming in November 2020.